Acalabrutinib
-
Acalabrutinib
structure -
-
CAS No:
1420477-60-6
-
Formula:
C26H23N7O2
-
Chemical Name:
Acalabrutinib
-
Synonyms:
ACP196;ACP-196;acalabrutinib;Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-;ACP196,Acalabrutinib;4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide;EOS-60753;(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
- Categories:
-
CAS No:
Description
Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.
ChEBI: Acalabrutinib is a member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a secondary carboxamide, a member of benzamides, a member of pyridines, an aromatic amine, a pyrrolidinecarboxamide, an imidazopyrazine, a ynone and a tertiary carboxamide.
Class: non-receptor tyrosine kinaseTreatment: CLL, SLL, MCLOral bioavailability = 25%Elimination half-life = 0.9 hProtein binding = 97.5%
Acalabrutinib Use and Manufacturing
Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL).
Recommended Suppliers of Acalabrutinib
-
![China]()
CN
5 YRS
Business licensed Certified factoryManufactory Supplier of Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst,Chemical Materials,Chem&Pharm Intermediates,Organic Intermediates,Feed AdditiveInquiryCAS No.: 1420477-60-6Grade: Industrial GradeContent: 99% -
![China]()
CN
5 YRS
Business licensedTrader Supplier of API,nutrition supplements,plant extract,peptide,HCGInquiryCAS No.: 1420477-60-6Grade: Pharmaceutical GradeContent: 98% -
![China]()
CN
1 YR
Business licensedTrader Supplier of Pharmaceutical intermediate/API， and fragrances APIInquiryCAS No.: 1420477-60-6Grade: Pharmaceutical GradeContent: 99% -
![China]()
CN
5 YRS
Business licensedTrader Supplier of PVC resin,pvc paste resin,melamineInquiryCAS No.: 1420477-60-6Grade: Industrial GradeContent: 99% -
![China]()
CN
3 YRS
Business licensedTrader Supplier of api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals,CATALYST AND AUXILIARY,FLAVORS AND FRAGRANCES,Chemical Pesticides,ADDITIVE
Learn More Other Chemicals
-
2,4-Dimethy diiphenylamine
25078-04-0
-
Ethyl (hydroxyimino)cyanoacetate potassium salt
158014-03-0
-
Orladeyo
1809010-50-1
-
4-(5- isopropoxy-2-methyl-4-nitrophenyl)pyridine Formula
1032903-62-0
-
2-Propyn-1-amine, N,N-diethyl-, radical ion(1+) Formula
125678-52-6
-
4-Methyl-N-(4-methylphenyl)-N-phenylbenzenamine Formula
20440-95-3
-
(1S,2R,3S,5R)-3-(Phenylmethoxy)-2-[(phenylmethoxy)methyl]-6-oxabicyclo[3.1.0]hexane Structure
110567-22-1
-
4-[2-(4-fluorophenyl)-5-(1-methylpiperidin-4-yl)-1H-pyrrol-3-yl]pyridine Structure
188343-77-3
-
What is oxiran-2-ylmethyl 2,2,2-trifluoroacetate
69161-63-3
-
What is Bis(4-methoxyphenyl)amine
101-70-2